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Pancreatic ductal adenocarcinoma (PDAC) has still a dismal prognosis. Locally advanced pancreatic cancer (LAPC) accounts for
the 40%of the newdiagnoses. Current treatment options are based on chemo- and radiotherapy regimens. Local ablative techniques
seem to be the future therapeutic option for stage-III patients with PDAC. Radiofrequency Ablation (RFA) and Irreversible
Electroporation (IRE) are actually the most emerging local ablative techniques used on LAPC. Initial clinical studies on the use
of these techniques have already demonstrated encouraging results in terms of safety and feasibility. Unfortunately, few studies on
their efficacy are currently available. Even though some reports on the overall survival are encouraging, randomized studies are
still required to corroborate these findings. This study provides an up-to-date overview and a thematic summary of the current
available evidence on the application of RFA and IRE on PDAC, together with a comparison of the two procedures.
1. Introduction
PDAC is one of the deadliest cancer types. It accounts for
about 7% of all cancer deaths and is actually the fourth cause
of cancer death in the United States [1]. Only 20% of PDAC
are resectable at time of diagnosis (with a 5-year survival of
less than 20%), while the majority of patients are candidates
only for chemotherapy or chemoradiotherapy according to
various protocols [2–4]. 40% of patients are diagnosed with
a locally advanced disease, with few chances to undergo
surgery even after neoadjuvant treatments. Median overall
survival (OS) reported for patients treated with upfront
surgery and adjuvant therapy is about 20–22 months [5–
7], while it is about 9.2–11.7 months for stage-III locally
advanced pancreatic cancer (LAPC) treated with Gemc-
itabine alone [8–10] and 9–13 months for patients treated
with chemo(radio)therapy [11]. Given that LAPC is nearly the
most frequent diagnosis to face and that downstaging occurs
only in 10–20% of patients [12], the novel local therapies,
such as Radiofrequency Ablation (RFA) and Irreversible
Electroporation (IRE), have been proposed as new treatment
options in the multimodal treatment of the disease [13]. The
aimof this paper is to evaluate and compare technical aspects,
indications, and results of the application of both RFA and
IRE on LAPC.
2. Physical Bases and Principles of Techniques
Local thermal or nonthermal techniques are applied to
ultimately induce irreversible cellular damage leading to cell
death via either apoptosis or coagulative necrosis. Physical
bases and principles of technique of both RFA and IRE are
briefly shown below.
2.1. RFA. RFA is an ablative therapy that, through the applica-
tion of a high-frequency alternating current, conveyed by one
or more needle electrodes, generates local high temperatures,
leading to coagulative necrosis and protein denaturation
inside neoplastic tissue. While at temperatures between 60
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Figure 1: US-guided intraoperative application of RFA tip.
and 100∘C immediate coagulation of tissue is induced, with
irreversible damage to the inner structure of the cells, using
100–110∘C, the tissue vaporizes and carbonizes [14]. At the
beginning of the application of RFA on PDAC, high morbid-
ity (0–40%) and mortality (0–25%) rates have been reported
[15]. Later, ex vivo studies demonstrated that an adjustment of
both temperature and length of the dispensed energy would
conduce to better outcomes with fewer complications [16, 17].
Although several temperatures have been used, ranging from
less than 30∘C to 90∘C according to the equipment used to
perform RFA [18, 19], it seems that the ideal parameters to
consider are actually represented by 90∘C for 5 minutes, with
a distance of 10 and 15mmbetween probe and duodenumand
portomesenteric axis, respectively [20]. The electrode must
be introduced inside the tumor under ultrasound or CT-
guidance and the procedure can be monitored in real time
by ultrasound with a safe distance of the RFA probe from
duodenum or portomesenteric vessels of 5–10mm (Figure 1).
The procedure can either be performed through laparotomy,
percutaneously, or through an endoscopic approach [21, 22].
These mini-invasive techniques could be useful to avoid
laparotomy, in patients unsuitable for surgery or in case of
LAPC of the body-tail of the pancreas without symptoms.
2.2. IRE. IRE is a nonthermal technique that induces cell
death. The ablative effect is based on the delivery of short
high-voltage electric current fields that induce cell death.The
application of short high-voltage electric pulses, conveyed
by one or more monopolar electrodes, causes the irre-
versible permeabilization of the lipid bilayer, the disruption
of intracellular homeostasis, and the activation of apoptotic
pathways, ultimately resulting in cell death of neoplastic
cells [30–36]. Interestingly, and differently from RFA, IRE
is able to preserve surrounding structures, such as the
underlying matrix that can work again as a scaffold for the
healing tissue, or the vital structures like nerves or vessels
[37–39]. Narayanan et al. in a retrospective review of 101
IRE procedures performed on different organs for tumors
abutting or encasing major vessels reported a rate of vascular
changes of only 4.4% (thrombosis ormild vascular narrowing
phenomena) demonstrating a very high rate of patency of
the major vessels in humans, after the application of IRE
[40]. The proper ability of IRE to preserve the vessels could
be a fundamental aspect when the tumor encases the major
peripancreatic vessels, when the application of RFA could
result as difficult, dangerous, and inefficacious (because of
the heat-sink effect). However, it has been advocated that the
cellular damage induced by IRE could be partially thermal.
In fact, in some conditions of high intensity, current applied
IRE can produce a coagulative necrosis similar to the one
produced by thermal techniques [41]. Dunki-Jacobs et al.
further investigated this aspect, concluding that IRE does not
produce significant thermal energy, at least using the settings
most commonly applied in clinical treatment. On the other
side, they demonstrated that the presence of metallic stent
could increase the risk of producing thermal injuries, because
of the conductivity of the metal [42]. This aspect might
be important in those patients carrying a biliary metallic
stent for jaundice palliation. Hence, it should be kept in
mind that IRE is not a “pure” nonthermal technique and
that it remains connected in some way with thermal effects.
Treatment planning of IRE is of utmost importance and
several tools are available to properly manage the application
of the technique [43–45]. Martin accurately described the
procedure with the ideal settings on pancreas [46, 47].
3. Indications and Contraindications
Preoperative work-up should always include routine labora-
tory tests (including CA 19-9 levels) and a 3-phase CT-scan
of the abdomen in order to assess exactly the location and the
dimension of the tumor, the type of vascular infiltration, and
the possible presence of abdominal metastases. Local ablative
therapies, such as RFA and IRE, should be allotted to those
tumors that show a local growth pattern without systemic
involvement and should be considered as consolidative ther-
apies in the multimodal therapeutic approach to LAPC. The
decision to perform one or the other should be taken by a
multidisciplinary group, considering the patients’ comorbidi-
ties and quality of life, the natural history of the tumor, and,
mostly, the response to medical oncological treatments. The
assessment of resectability of LAPCafter neoadjuvant therapy
is still difficult [48]. In the FOLFIRINOX era, imaging seems
to have no longer ability in determining the real response rate
after neoadjuvant therapy [49]. In the future, RFA and IRE
will be appliedmore often as “salvage” cytoreductive therapies
or in the context of properly designed clinical trials, at least
until randomized controlled trials will not demonstrate their
oncological efficacy. Furthermore, it is of paramount impor-
tance that RFA and IRE should be performed selectively
in high-volume HPB centers, and, for percutaneous-only
approaches, by experienced interventional radiologists.
3.1. RFA. Indications are as follows. The most common
worldwide application of RFA on PDAC is represented by the
treatment of stage-III patients, either in case of no further
response to standard systemic treatments or as an upfront
option at the time of diagnosis [15, 16, 18, 28, 50–58]. How-
ever, some studies included also stage-IV metastatic patients
Gastroenterology Research and Practice 3
23
4 4
1
23
Figure 2: Example of a computerized model of the application of
a 4-needle IRE technique. The yellow oval represents the tumor.
Crossing blue beams represent the energy developed between each
couple of probes.
[18, 19, 59, 60], probably to induce a positive modulation
of the immune system [61]. Recently, the application of
RFA upfront has been justified on the basis of a presumed
immunological antitumoral stimulation aroused byRFA [50];
a randomized controlled study to prove or to disown it is
currently running. However, RFA should be considered as
a new tool in the surgeon’s toolbox, in the context of a
multidisciplinary approach to PDAC.
Tumor diameter is not a crucial parameter in the eval-
uation of the application of RFA as the technique itself
allows ablating up to 5 cm or more [62]. Unfortunately,
because of the proximity of vital structures surrounding
PDAC (infiltrated by definition in LAPC), the whole ablation
of the tumor would result in being too risky. Then, it is
preferred to treat the biggest possible area, performing also
pull-backs of the tip, leaving a “security ring” at the periphery
of the tumor in order to avoid thermal injuries of the nearby
structures [63]. This viable tissue at the periphery of the
tumor will later be the target of the radiotherapy, to complete
the ablation of the tumor [17].
Contraindications are as follows. RFA can interfere with
implanted pacemakers and cardioverter defibrillators due to
electromagnetic energy [64]. Hence, a cardiac evaluation is
recommended in this special subset of patients, for a possible
resynchronization of these devices.
3.2. IRE. Indications are as follows. Almost all the applica-
tions of IRE on PDAC are on stage-III LAPC [23, 24, 27, 47,
65–71]. Narayanan et al. reported three cases of application
of IRE on stage-IV patients with centimetric liver metastases
from PDAC and two cases of application of IRE as a “bridge”
therapy in LAPC before submitting the patients successfully
to a radical surgical resection [72]. Simultaneously, some
papers report promising results on the use of IRE for margin
accentuation, as a technique to reduce the rate of R1 resections
in case of locally advanced/borderline resectable PDAC [24,
65, 68, 73]. In general, IRE works better on tumor sizes
that are 3 to 3.5 cm and it is important to plan the ablation
technique properly (Figure 2) in order to treat the whole
tumor [74]. In addition, the application of IRE seems to be
more appropriate than RFA when the tumor encapsulates
the superior mesenteric artery. In fact, the application of
multiple needles allows bracketing the artery and treating.
Furthermore, the negligible amount of heat associated with
IRE allows safe and efficacious ablations.
Contraindications are as follows. In general, electric fields
applied to human body can cause arrhythmias; hence, it
is of utmost importance to reduce this risk synchronizing
pulsing with the heart rhythm, using a dedicated device
[75]. For these reasons, IRE is contraindicated in patients
with pacemakers or with cardiac arrhythmias. Moreover,
a metallic biliary stent should be removed intraoperatively
before IRE, because the presence of the metal could increase
the risk of thermal injury [70].
4. Oncological Outcomes
All the results regarding the oncological outcomes of the
application of RFA and IRE on PDAC are biased by the nature
itself of the studies. The reports include very heterogeneous
populations of patients, with either stage-III or stage-IV
disease.There are no randomized controlled studies available.
Most of them were created as phase-I studies in order to
demonstrate the safety of the techniques; then, oncological
outcomes were only secondary goals. Despite these intrinsic
problems, some encouraging results can be extracted.
4.1. RFA. Given that all patients treated with RFA will
relentlessly progress [16, 53, 57, 60], some papers report good
oncological results obtained with the use of RFA on PDAC.
Spiliotis et al. reported a reassuring mean survival of 30
months for patients suffering from PDAC treated with RFA,
compared to the 13 months’ survival for patients receiving a
standard systemic treatment (𝑝 = 0.0048) [18]. Giardino et
al. cited a median overall survival (OS) for their whole series
(𝑛 = 107) of 25.6months, 14.7months in the group of patients
receiving RFA plus several possible systemic treatments, and
25.6 months in the group treated with primary treatments
plus RFA plus further systemic treatments (𝑝 = 0.004).
Interestingly, those patients who received this latter ther-
apy, the so-called “triple approach strategy,” with RFA plus
radiochemotherapy plus intra-arterial chemotherapy with
further systemic treatments, had an OS of 34.0 months [17].
4.2. IRE. Despite the increasing number of papers reporting
the application of IRE on PDAC, none of these studies
is designed to demonstrate the oncological efficacy of the
procedure. In fact, they mostly deal with safety and feasibility
issues and for this reason the populations considered are
not ideal models for the analysis of oncological outcomes.
Table 1 shows the studies reporting data on the efficacy of
IRE; however, all these results must be considered cautiously.
Interestingly, two papers described five cases of downstaging
with R0-resections of LAPC treated with percutaneous IRE
[26, 27].
A recent paper from Martin et al. reports an outstand-
ing median OS of 24.9 months (range 12.4–85 months;
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Table 1: Efficacy of IRE on PDAC.
Author Number ofpatients Approach Type of study
Survival
(mo.)
Martin et al. [23] 54 Open (52)Percutaneously (2)
Propensity-matched
comparison with
standard chemo- or
chemoradiation
20.2
Martin et al. [24] 200 Open Data frommulticenter registry 24.9
Trueba-Arguin˜arena
et al. [25] 1 Percutaneously Case report f-up 12mo.
Narayanan et al. [26] 43 Percutaneously Prospective 16.2
Belfiore et al. [27] 20 Percutaneously Retrospective 12.9
Pai et al. [28] 5 Percutaneously Phase-1 safety andfeasibility
Range
1–6mo.
Paiella et al. [29] 10 Open Phase-1 safety andfeasibility
Median 6.4,
range
2.9–15.9
𝑛 = 200), for patients treated with IRE in situ or pancreatic
resections with major vascular resections and IRE for the
margin accentuation, after 6 months (median) of induction
chemotherapy or chemo(radio)therapy [24]. As the authors
state in the paper, the population considered is made of
highly selected patients and this represents an important
selection bias. However, these results are very surprising
and encouraging, especially if compared with the historical
populations of patients reported in literature suffering from
LAPC.
Recently, Philips et al. reported an increased risk of accel-
erating the tumor growth after the application of incomplete
sessions of IRE in a murine model. This worrisome finding
should be further clarified and possibly verified in clinical
scenarios [76].
5. Complications
The majority of the complications caused by local ablative
techniques are consequence of an uncontrolled heating of the
structures surrounding the tumor, rather than a direct lesion
caused by the tip of the probe used. Therefore, obviously, it
is of paramount importance to plan properly the procedure,
setting the parameters according to location, dimensions, and
morphology of the tumor.
5.1. RFA. The first clinical applications of RFA were afflicted
by a high rate of morbidity and mortality, ranging from 0
to 40% and from 0 to 25%, respectively [15]. Once the tem-
perature was lowered from 105 to 90∘C for 5 minutes’ length,
the reported number of complications reduced in parallel [16,
17]. The deaths related to RFA were most commonly caused
by gastrointestinal hemorrhages. The most recent cohort of
patients treated with RFA comes again from Girelli et al.
They reported a reduction of the morbidity rate to 8%, with
a mortality rate of 0% [50]. The overall reported rates of
RFA-related complications andRFA-relatedmortality are 13.6
and 1.5%, respectively [13]. The most common complications
reported in literature are gastrointestinal hemorrhages and
minor local bleedings, acute pancreatitis (mild or severe),
pancreatic and biliary fistulas, duodenal injury (thermal or
direct), and portal vein thrombosis. It is suggested to cool the
duodenum during the procedure with a cold saline solution
administered using the nasogastric tube, to preserve it from
the possible thermal injury [20].
5.2. IRE. A recent systematic review reported an IRE-related
complication rate of 13%, with an IRE-related mortality
of 2% [13]. The overall reported complications rate of the
percutaneous approach is 29% [77]. Martin et al., in a recent
study with a population of 200 patients suffering from LAPC
treated with IRE, showed an overall rate of adverse events of
37% (74 patients with 149 overall complications) and a mor-
tality rate of 2% [24]. The largest single-center percutaneous
series of 50 IRE described an overall number of 27 complica-
tions [26]. The most common complications (including both
percutaneous and open techniques) described after the use of
IRE on pancreas are pancreatitis, pneumothorax, hematoma,
abdominal pain, bile leakage, pancreatic leakage, duodenal
leakage, duodenal ulcer, and deep vein thrombosis.
6. Ablative Techniques and Imaging
One of the most interesting and useful aspects of the appli-
cation of the ablative techniques on PDAC is the possibility
to appraise the amount of tissue ablated and the relationship
between the treated area and tumor margins.
6.1. RFA. For RFA, and in general for “thermal techniques,”
the gold standard of imaging is represented by cross-sectional
imaging via helical CT-scan, rather than ultrasonography
[78]. A postablative hypointense area can be observed as
result of the treatment (Figure 3). At our institution, we
perform a three-phase contrast-enhanced CT-scan of the
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Figure 3: (a) Preoperative CT-scan of a locally advanced pancreatic cancer. (b) Post-RFA perfusion CT-scan, showing a postablative area of
decreased perfusion within the head of the pancreas. Copyright Chirurgia del Pancreas Verona.
(a) (b)
Figure 4: (a) The tip for RFA is placed inside the tumor under US-guidance. (b) During RFA, the lesion becomes immediately hyperechoic.
abdomen at postoperative days 7 and 30. During the proce-
dure, ultrasonography can both guide the tip and detect the
immediate results of the thermal damage (Figure 4).
6.2. IRE. Because of the nonthermal noncoagulative action
of IRE and because of the consequent preservation of the
vessels, the application of contrast-enhanced CT-scan after
IRE would not have the same results as for RFA. Several
techniques have been used to evaluate the effect of the
application of IRE. Magnetic resonance electrical impedance
tomography (MREIT) seems to be able to identify the areas
with insufficient electric field, in order to label potential
untreated zones after IRE [79]. Either contrast-enhanced or
diffusion weighted MRI seems to be able to depict the tissue
zones ablated with IRE [80–82]. Even if using a swine model,
a recent study stated that the best identification of tissue
ablation after IRE is obtained with portal vein phase CT-scan.
Anyway, differently from RFA, during CT-scan, a contrast
enhancement can be appreciated on themore delayed venous
phase, due to the congestion of blood in the tumor vessels
[32, 83, 84]. Ultrasound findings during and after IRE could
be useful to evaluate the approximate area of ablation. In
the acute phase, a hypoechoic area can be registered, with a
hyperechoic external rim that forms 90–120minutes after the
treatment [85, 86]. However, Martin et al. state that an early
postoperative scanning after IRE should be performed only
to rule out possible complications (deep vein thrombosis)
and not to evaluate ablation efficacy [24]. It still has to be
evaluated if a serum CA 19-9 level decrease could be used as
predictor of efficacy.
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7. Ablative Techniques and Immune System
The strongest factor supporting the clinical application of the
ablative techniques, especially of RFA, is represented by their
positive antitumoral effect on immune system. Nowadays,
thanks to the several studies that have been published, RFA
is called prudently “endogenous vaccine” for PDAC. How
strong is this power and which are the best timing and proper
methods to use it remain to be established.
7.1. RFA. All the processes involving the modulation of
immune system have been exhaustively described by Chu
and Dupuy [87]. While the direct effect of RFA is clearly
represented by the necrotic area immediately identifiable
after the procedure, on the other hand, the indirect effects
are on the viable zone adjacent to this area (transition or
peripheral zone).The cells populating the peripheral zone are
affected by the RFA in terms of alteration of metabolic endo-
cellular processes that makes them quite sensible to further
cytolytic therapies, such as chemo- or chemoradiotherapy.
These effects result, ultimately, in the almost total destruction
of the tumor. In parallel to this “local” action, RFA can cause
a “systemic” immune response involving proinflammatory
cytokines [88–90], lymphocytes (T-, B-, and NK-types) [91–
94], and antibodies [95] that are responsible for acquired
antitumoral antigen-specific immunity [96, 97] that could
confer better survival in some patients treated with RFA. It
also seems promising to use the synergic use of RFA together
with topic specific cytolytic agents or with immunotherapy
with monoclonal antibodies or vaccine [98]. However, most
of the findings described come from experimental models
or from in vivo results from organs other than pancreas. Of
course, there is need for more preclinical models, investiga-
tional studies, and large randomized controlled clinical trials
to demonstrate the effects of RFA on PDAC selectively.
7.2. IRE. The immune system involvement after IRE has not
been thoroughly investigated yet.
Some reports support the evidence that since the proteins
are not denatured in IRE (differently from in RFA), in theory,
this could result in a weak specific antigenic stimulation
against the tumor. In fact, Al-Sakere et al., using murine
models of sarcoma treated with IRE, showed that there is
no local infiltration of tumor cells among the treated tissue.
An early and prolonged decrease in both T lymphocytes
(both CD4+ and CD8+) and antigen presenting cells can be
detected within a couple of hours after IRE [99]. As they
support, this is a demonstration that IRE does not need the
involvement of the immune system to kill neoplastic cells and,
for this reason, it could be applied on immunosuppressed
patients too. On the other hand, other reports reached the
evidence that both local and systemic immune antitumoral
stimulation are enhanced after IRE [100, 101]. This aspect
could be referred to the peculiar type of cellular death caused
by IRE: the activation of the apoptotic processes leads to
the release of intact and stimulating endogenous tumoral
antigens able to induce a strong global antitumoral activity.
Ultimately, according to Neal II et al., IRE would be able to
generate the “three signals’ sequence” that is mandatory for
the production of a cytotoxic T-cell response [101].
These conflicting reports demonstrate how far we are
from the understanding of the exact involvement of the
immune system and how much we need further preclinical
and clinical models.
8. Conclusions
RFA and IRE represent an innovation on the multimodal
treatment of LAPC. The undeniable advantages connected
with the use of these techniques are represented by low
morbidity, reduced costs, possible percutaneous application,
almost selective action with preservation of peritumoral
tissues, possible application to patients at a high-risk for
surgery, and suspected positive immune stimulation. More-
over, taking into account their positive effect on the immune
system, they could be potentially very useful in those patients
that, somehow, show an indolent disease, with a prevalent
local growth and without a wide systemic involvement.
Nevertheless, as for any other technology introduced
in medical practice, RFA and IRE have to be evaluated
prospectively and systematically according to the IDEAL
framework for evaluation of surgical innovation [102]. In the
IDEAL paradigm for the introduction of new technologies in
surgery, the application of RFA and IRE on LAPC is still stuck
on the 2a phase where few people still adopt the technique,
where the patients are selected, where the outcomes are
mostly safety and feasibility, and where the clinical outcomes
are timidly reported. Hence, the current available evidence
is still not sufficient to permit conclusions about long-term
benefits.
Nowadays, the patients suffering from LAPC are still
waiting for answers that medical oncologists cannot give.
Surgery and new ablative technologies can play an important
role in giving hope, prolonging survival, and improving
quality of life of the patients suffering from LAPC. However,
we must move toward a rigorous evaluation of these new
procedures through the creation of appropriate randomized
controlled studies.
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